The Sims 3 | Perfect Genetics Challenge Part 21: Unlucky
In this part, we change Hunter #39;s hairstyle and give birth to another baby. The Sims 3 Perfect Genetics Playlist: https://www.youtube.com/playlist?list=PL0B...

By: simplyapril

View post:
The Sims 3 | Perfect Genetics Challenge Part 21: Unlucky - Video

Recommendation and review posted by Bethany Smith

MENDEL EXPLAINING GENETICS CROSSES 2

By: Walter Jahn

Here is the original post:
MENDEL EXPLAINING GENETICS CROSSES 2 - Video

Recommendation and review posted by Bethany Smith

Under the Microscope: Genetics
For decades, Idaho Fish and Game stocked hatchery rainbow trout often on top of native cutthroat trout. Cross-breeding between the two groups of fish became ...

By: idahofishgame

View post:
Under the Microscope: Genetics - Video

Recommendation and review posted by Bethany Smith

Lets Play The Sims 3 Perfect Genetics/100 Baby Challenge Live Stream Part 16
Perfect Genetics and 100 Baby Challenge in 1 -- Watch live at http://www.twitch.tv/gbabychallenger.

By: GBabyChallenger

Read more here:
Lets Play The Sims 3 Perfect Genetics/100 Baby Challenge Live Stream Part 16 - Video

Recommendation and review posted by Bethany Smith

Gage Green Genetics update
18 over MMMP patient and caregiver in full compliance. This is a test grow for thesocialgrow and gage green Genetics. Plants are doing very good nice and green.

By: BolagnaSheetsMD .

Here is the original post:
Gage Green Genetics update - Video

Recommendation and review posted by Bethany Smith

MINECRAFT - 1.7.2 - Avanced Genetics
Primer mod que utilizaremos en esta nueva serie, pico ser todo! Descarga del mod: http://ag.teamdna.de/ Estoy en twitter! @jerrypkm Link de los tutoriales de Redstone: http://www.youtube.com...

By: MinecraftCoyoacan

See the rest here:
MINECRAFT - 1.7.2 - Avanced Genetics - Video

Recommendation and review posted by Bethany Smith

PIONEERING genetics company, Landcatch, Troutlodge and Hendrix Genetics have concluded a Memorandum of Understanding (MoU) aiming to significantly extend their global share of the Atlantic salmon and rainbow trout markets.

Scottish company, Landcatch, which supplies Atlantic salmon eggs and smolts as well as cutting-edge genetic services to the international aquaculture industry, has signed a MoU to become a 45 per cent shareholder in Seattle-based Troutlodge, Inc, the worlds largest rainbow trout egg producer.

It will mean Landcatch diversifying into a new species for the first time, a strengthening of the Hendrix Genetics aquaculture operations, as well as enhanced support and growth for Troutlodge, with all three companies enthusiastic about the opportunities that will come from greater positioning in world aquaculture.

The deal includes:

A joint venture (JV) that will see a new company, Landcatch-Troutlodge Chile SA, being formed to establish an independent Atlantic salmon breeding programme, backed by genetics research. It aims to capture a substantial market share of salmon eggs in Chile within 3-5 years.

Troutlodge Chile SAs existing trout egg production and supply operation will be developed and expanded. It is also planned to develop a pedigree coho salmon programme to service the Chilean industry. With all three species combined, it is expected that the employment will grow significantly.

A Genetics Support Agreement (GSA) that will ensure all Troutlodge breeding programmes will now be supported by Landcatch and Hendrix Genetics, combining pioneering genetic technologies transferred from the salmon and livestock industries with Troutlodges decades-long genetic improvement programme.

Neil Manchester, Managing Director of Landcatch, said: This is a very exciting investment, which will see Troutlodge and us make a further significant impact in world aquaculture.

It increases our sustainability by working with such a credible partner; it allows us to become re-established in Atlantic salmon egg production in Chile and it enables us to pursue a significant expansion strategy with the aim of becoming one of the main global players in salmon and trout.

Read the original:
Exciting new international aquaculture collaboration

Recommendation and review posted by Bethany Smith

Buy Photo

AgReliants Genetics was presented a $20,000 forgiveable loan from the Boone County Economic Growth Corporation (BCEGC) Tuesday afternoon. Pictured are, from left, Craig Newman, president and CEO of AgReliant Genetics, Tom Lee, Des Moines Area Community College Boone campus provost, Steve Woodall, AgReliant Genetics location manager, and Frank Lynch, AgReliant Genetics vice president of operations. Photo by Whitney Sager

The Boone County Economic Growth Corporation (BCEGC) officially presented AgReliant Genetics with a $20,000 forgivable loan Tuesday afternoon at the facility west of Ogden.

The forgivable loan played a role in bringing the business to Boone County, said Bob Fisher, BCEGC executive director.

Steve Woodall, AgReliant Genetics location manager, said they are about to begin their second harvest season, after a successful first year. Despite the weather challenges this growing season has experienced, the facility plans to begin harvesting next week.

The facility currently has a 500-bushel capacity, but could go up to 1 million bushels, if needed.

Woodall also spoke of the willingness of businesses in Boone County to supply AgReliant with supplies they need and how that has been a great benefit for the facility.

Its been good for us and we appreciate it, Woodall said.

The site is still under construction, though work should be finished by the first of the year. Future plans are in place to expand the facility even further.

Its exciting to see what was nothing but dirt and now what it has become, said Frank Lynch, vice president of operations at AgReliant Genetics.

Originally posted here:
Forgiveable loan presented to AgReliant Genetics

Recommendation and review posted by Bethany Smith

New York, California (PRWEB) August 28, 2014

The Manhattan Regenerative Medicine Medical Group announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia M. Smyrniotis, Medical Director.

The seminars will be held on Wednesday, September 3, 2014, at 2pm and 4pm at the City Limits Diner, at 135 Harvard Avenue, Stamford, CT 06902. Please RSVP at (917) 410-7391.

The Manhattan Regenerative Medicine Medical Group is an affiliate of the Miami Stem Cell Treatment Center, which abide by investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of degenerative and chronic inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center only use Adult Autologous Stem Cells from a person's own fat No embryonic stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Parkinsons Disease, Stroke, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, and degenerative orthopedic joint conditions. For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Manhattan Regenerative Medicine Medical Group or Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Nia directly at (917) 410-7391, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

About Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center: The Manhattan Regenerative Medicine Medical Group and The Miami Stem Cell Treatment Center is an affiliate of the Cell Surgical Network (CSN); they are located in Manhattan, NY; Miami, Boca Raton, and Orlando, Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection; and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information visit our website: http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

Read more:
Adult Stem Cell Public Lecture New York Manhattan Regenerative Medicine Medical Group

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

28-Aug-2014

Contact: Robert Nellis newsbureau@mayo.edu 507-284-5005 Mayo Clinic

ROCHESTER, Minn. A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform that uses network biology methods to aid stem cell engineering. Details of CellNet and its application to stem cell engineering are described in two back-to-back papers in the journal Cell.

"This free platform has a broad range of uses for all types of cell-based investigations and can potentially offer help to people working on all types of cancer," says Hu Li, Ph.D., investigator in the Mayo Clinic Center for Individualized Medicine and Department of Molecular Pharmacology & Experimental Therapeutics, and co-lead investigator in the two works. "CellNet will indicate how closely an engineered cell resembles the real counterpart and even suggests ways to adjust the engineering."

The network biology platform contains data on a wide range of cells and details on what is known about those cell types. Researchers say the platform can be applied to almost any study and allows users to refine the engineering process. In the long term, it should provide a reliable short cut to the early phases of drug development, individualized cancer therapies, and pharmacogenetics.

CellNet uses 21 cell types and tissues and data from 56 published human and mouse engineering studies as a basis for analyzing and predicting cell fate and corresponding engineering strategies. The platform also offers classification scores to determine differentiation and conversion of induced pluripotent stem cells. It reveals incomplete conversion of engineered microphages and hepatocytes. CellNet can be used for interrogation of cell fate following expression profiling, by classifying input by cell type, quantifying gene regulatory network status, and identifying aberrant regulators affecting the engineering process. All this is valuable in predicting success of engraftment of cancer tumors in mouse avatars for cancer and drug development research. CellNet can be accessed at cellnet.hms.harvard.edu.

###

Co-lead authors with Dr. Li are Patrick Cahan, Ph.D., and Samantha Morris, Ph.D., of Boston Children's Hospital. The senior investigators are George Q. Daley, M.D., Ph.D., Director of the Stem Cell Transplantation Program at Boston Children's and senior investigator on both studies and James Collins, Ph.D., Core Faculty member at the Wyss Institute and the William F. Warren Distinguished Professor at Boston University, co-senior investigator on one of the studies.

Investigators are supported in part by the National Institutes of Health, specifically, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute; the Children's Hospital Stem Cell Program; the Howard Hughes Medical Institute; Alex's Lemonade Stand Foundation; the Ellison Medical Foundation; the Doris Duke Medical Foundation; the Mayo Clinic Center for Individualized Medicine and the Mayo Clinic Center for Regenerative Medicine.

Go here to read the rest:
New tool aids stem cell engineering for medical research

Recommendation and review posted by simmons

STEM CELL THERAPY: with DR ANDREW J. ROCHMAN
Dr. Andrew J Rochman is a leader in advanced surgical techniques, a native New Yorker and a Board-Certified Surgeon. His current undertaking involves promoting an educational advocacy in MODERN...

By: Modern Pain Relief

Excerpt from:
STEM CELL THERAPY: with DR ANDREW J. ROCHMAN - Video

Recommendation and review posted by simmons

By Ciara Curtin

Jeanne Loring and her Scripps Research Institute colleagues transplanted a set of cells into the spinal cords of mice that had lost use of their hind limbs to multiple sclerosis. As the experimentalists expected, within a week, the mice rejected the cells. But after another week, the mice began to walk.

We thought that they wouldnt do anything, says Loring, who directs theCenter for Regenerative Medicineat Scripps. But as her lab has since shown numerous times, and published in Stem Cell Reports, something that these particular so-called neural precursor cells dobeforethe immune system kicks them out seems to make the mouse better.

The cells Lorings team used are derived from induced pluripotent stem cells, which are mature cells, such as skin cells, that have been coaxed with a combination of chemicals to return to an earlier stage of development.

Induced pluripotent cells, also known as iPS cells, pose a number of opportunities for medicine. For instance, Loring is using iPS cells from Parkinsons disease and multiple sclerosis patients to reconstitute cell types that may be damaged in people with those conditions. She is also using them to test how certain drugs or treatments may affect damaged cells in people with conditions such as autism spectrum disorders.

Loring (front row, center) with the Loring Lab Group at the Center for Regenerative Medicine

Loring says no viable long-term treatments exist for the diseases her team has been working on, including Alzheimers disease, Parkinsons disease, and multiple sclerosis, Thats where the need is, she says.

The neural precursor cells that Loring has been using in the mice with MS are young cells that havent quite gotten to the point of being nerves yet. Only certain types of these cells have such a dramatic Lazarus-like effect on the affected mice, but Lorings team can readily identify them based on DNA analysis.

Even so, theyre not yet ready to treat human MS patients with the approach, she says. First, the researchers want to identify what the cells producea protein, perhaps, or a set of proteinsthat allows the mice to walk.

For other diseases, however, researchers are closer to being ready to transplant working versions of reprogrammed cells into sick people.

More here:
Could Reprogrammed Cells Fight 'Untreatable' Diseases?

Recommendation and review posted by simmons

44 1 Mr. Sun -spinal cord injury,paraplegia (Male, 54-year-old)- Before stem cell treatment
Mr. Sun, 54 years old, happened to meet a car crash in February, 2010, which caused him T9-T12 vertebras fracture, the spinal cord injury of relevant segments, paraplegia. He received 1st...

By: Stem Cells

Read more:
44 1 Mr. Sun -spinal cord injury,paraplegia (Male, 54-year-old)- Before stem cell treatment - Video

Recommendation and review posted by sam

MIAMI - When Bruce Daily woke up after having lumbar surgery a year ago, he realized he couldn't move the right side of his body.

"It took me a long while to figure out I wasn't gonna walk again," he said. "I knew I was down."

Daily, 69, had gone in for lumbar surgery at the University of Miami hospital and had an ischemic stroke while under anesthesia. An ischemic stroke results from an obstruction in a blood vessel that blocks the blood from getting to the brain.

Because he was unconscious, he missed the four-to-five hour-window to apply the tissue plasminogen activator, or tPA, the only medication available to treat ischemic strokes. The medication dissolves the clot, restoring blood flow to the brain.

But while he missed that chance, he was right on time to meet Dr. Dileep Yavagal, a neurosurgeon who practices at the University of Miami and Jackson Memorial hospitals. Yavagal was enrolling patients in RECOVER-stroke, a clinical trial treating recent stroke patients with stem cells from their bone marrow and applying them directly into the carotid artery, one of two arteries that supply the neck and head with blood. Daily was one of 47 patients nationwide who qualified for the study.

The study is funded by Cytomedix, the company that developed the technology to extract stem cells from bone marrow. The firm chose Yavagal to lead a national blind study at the end of 2012.

Yavagal enrolled 13 patients at the University of Miami/Jackson Memorial Hospital, between the end of 2012 and January of 2014. So far, the initial three-month results have revealed that the marrow cells are not doing any damage, and there was no clear difference between those who received the cells and those who didn't. The study's one-year final results will be revealed in January.

"There is severe need for developing treatment for ischemic stroke, and stem cells are the most promising," said Yavagal, whose own research is still in its initial phase, focusing on using a healthy donor's bone marrow stem cells versus the patient's own marrow.

Stroke, the leading cause of adult disability in the United States, and the No. 4 cause of death in the country, causes 130,000 deaths a year in the U.S., according to the Centers for Disease Control and Prevention.

Yavagal, associate professor of clinical neurology and neurosurgery and the director of interventional neurology at the University of Miami's Miller School of Medicine, said that restricted mobility or loss of speech resulting from a moderate to severe stroke can be devastating because patients often become dependent on someone else for daily activities.

See the rest here:
Can stem cells help mobility after stroke?

Recommendation and review posted by Bethany Smith

By RTT News, August 26, 2014, 06:00:00 PM EDT

(RTTNews.com) - GlaxoSmithKline plc (GSK, GSK.L) said Tuesday the U.S. Food and Drug Administration approved a supplemental New Drug Application for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.

Severe aplastic anaemia, or SAA, is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets. Eltrombopag, an oral thrombopoietin (TPO) receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.1

"FDA approval of Promacta addresses a significant treatment need for this very rare but serious blood disorder in those who have failed current treatment options," said Paolo Paoletti, president of Oncology, GSK.

Promacta gained Breakthrough Therapy designation status from the FDA in January 2014 and Priority Review in April 2014. Today's approval by the FDA is based on results from an investigator-sponsored Phase II study conducted by the National Heart, Lung and Blood Institute at the National Institutes of Health.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Visit link:
GSK: FDA OKs Promacta SNDA In Patients With Aplastic Anaemia

Recommendation and review posted by Bethany Smith

Stem cells heal pooches in pain MIKE MATHER

NICK REED/Fairfax NZ

HAPPY HOUND: Shiloh with owner Adele Holland. She is a different dog since having stem cell injections to relieve arthritis pain, Holland says.

Three years ago australian shepherd dog Shiloh was diagnosed with a severe case of degenerative arthritis that left her limping slowly towards her deathbed.

As time went on, and to the dismay of her Horotiu family, Shiloh became increasingly stiff, was soon no longer able to jump, could barely walk without pain, and eventually had to be carried outside to the toilet.

But, remarkably, the 10-year-old pet is not only still alive today, she is walking and jumping without a trace of pain.

It's a physical improvement her owner Adele Holland describes as "nothing short of a miracle".

Shiloh's recovery is something dozens of arthritic Waikato dogs have now experienced after stem cell injections, a treatment technique adopted by Hamilton veterinarian practice CareVets.

Veterinarian Ivan Aleksic said Shiloh was the first dog to receive stem cells. His practice had successfully repeated the $2600 treatment on more than 40 dogs with arthritis. He described stem cells as "the body's own repair cells".

"They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. They can divide and turn into tissues such as skin, fat, muscle, bone, cartilage and nerve to name a few.

More:
Stem cell treatment helps arthritic dogs

Recommendation and review posted by Bethany Smith

27.08.2014 - (idw) Max-Delbrck-Centrum fr Molekulare Medizin (MDC) Berlin-Buch

Stem cells are essential for the repair of muscle damage, but all attempts to manipulate human muscle stem cells for therapy have thus far failed. Now Dr. Andreas Marg and Prof. Simone Spuler of the Experimental and Clinical Research Center (ECRC), a joint cooperation between the Max Delbrck Center (MDC) and the Charit, have shown how this might work. They developed a method in which they did not isolate the muscle stem cells, but rather cultivated, proliferated and transplanted them along with their muscle fibers. Using this method in mice, they were able to successfully regenerate muscle tissue. Thus they have opened the door for the use of muscle stem cells to treat muscle diseases.* "Muscle stem cells, which we also refer to as satellite cells, can awaken in their stem cell niche after decades of quiescence and can then repair damaged muscle tissue," Professor Spuler explained. At the ECRC in Berlin-Buch, the neurologist heads the University Outpatient Clinic for Muscle Disorders and the Department of Muscle Sciences. She and her team are exploring the causes of muscle diseases. Evidence shows that satellite cells are active in people with severe muscle diseases such as Duchenne muscular dystrophy, a severe genetic disease in which the muscles degenerate. "But at some point, she added, the reservoir is depleted of muscle stem cells and muscle wasting cannot be stopped."

All attempts to rebuild muscle tissue by transplanting satellite cells in patients with Duchenne muscular dystrophy have failed. The transplanted cells are not viable. Furthermore, the use of other cells with potential to regenerate muscle cells has shown little success. These cells have only limited potential to regenerate muscle. But how is it possible to nevertheless use the bodys own self-renewal potential and the reconstruction potential of satellite cells?

The offer of developmental biologist Professor Carmen Birchmeier (MDC) to participate in the network project on satellite cells (SatNet) of the Federal Ministry of Education and Research pointed Professor Spuler and her co-workers in the right direction. One of the topics of the project was to elucidate why satellite cells rapidly lose their regeneration potential if they are kept in a cell culture. This led to the idea to cultivate the satellite cells together with the surrounding muscle tissue to see whether the cells, if they remain in their accustomed milieu, might possibly regenerate better.

Muscle biopsy specimens from young and old donors After due approval and written, informed consent, Professor Spuler and Dr. Marg obtained specimens of fresh thigh muscle tissue from patients between 20 and 80 years of age from neurosurgeons of Helios Klinikum Berlin-Buch, which like the MDC is located close to the ECRC.

From the biopsy specimens, Professor Spuler and her co-workers dissected more than 1000 muscle fiber fragments, each about 2-3 millimeters long. Remarkably, the researchers found the number of stem cells in the individual tissue specimens to be independent of the age of the donor and that thousands of myoblasts developed from a small number of satellite cells. After further developmental steps, these fuse into muscle fibers.

Dr. Marg: Satellite cells need to have their local milieu around them Professor Spuler and her co-workers cultivated the muscle fiber fragments with the satellite cells, initially for up to three weeks. During this time, the satellite cells increased by 20- to 50-fold, but numerous connective tissue cells also developed in these cultures. To prevent this, the researchers concurrently subjected the muscle fragments to oxygen deprivation (hypoxia) and to cooling (hypothermia) at 4 degrees Celsius. Under these conditions, only satellite cells are able to survive in their stem cell niche, in contrast to the connective tissue cells. Apparently, the satellite cells receive the proper nutrients in their own local milieu, Dr. Marg said.

First success in mice The ECRC researchers then tried out their therapy approach in mice in which muscle regeneration had been inhibited by irradiation. They grafted the muscle fragments containing the satellite cells, which following the hypothermia had been kept for two weeks in culture dishes, into the tibalis anterior muscle. The researchers found that the muscles of animals that had been treated with these fiber fragments regenerated particularly well.

Objective: to couple satellite cells with gene therapy However, a genetic muscle disease cannot be successfully treated alone by transplanting muscle fragments. Professor Spuler: The idea is therefore to equip the satellite cells additionally with a healthy gene that repairs the defective gene and then to transfect it with the aid of a non-viral gene taxi into the muscles to be treated. In a first experiment with a reporter gene in the Petri dish, Professor Spuler and her co-workers proved that this is possible in principle. The reporter gene fluoresces green when it is transfected into the satellite cell. As gene taxi the researchers use the Sleeping Beauty transposon a jumping gene that can change its position in the genome. This transposon technique was developed several years ago by Dr. Zsuzsanna Izsvk (MDC) and Dr. Zoltn Ivics (Paul Ehrlich Institute, Frankfurt) and is considered to be a very promising delivery vehicle (vector) for gene therapy.

Before the method developed by Professor Spuler and her group can be used to benefit patients, some hurdles remain to be taken. So far, the transplantation has succeeded in small mice muscles. In clinical trials, the scientists and physicians want to determine whether this technique can be used in large human thigh muscles, which may be severely altered due to a muscular disease.

More:
New Research Method Opens Door to Therapy with Human Muscle Stem Cells Promising Method Developed

Recommendation and review posted by Bethany Smith

MANCHESTER, England, Aug. 20 (UPI) -- Acral melanomas -- a rare form of skin cancer and the type that claimed the life of reggae musician Bob Marley -- are genetically distinct from more common types of skin cancer, according to new research by scientists in the United Kingdom.

A team of researchers from the Cancer Research U.K. at The University of Manchester compared the DNA of several acral melanoma tumors to several other types of skin cancer tumors. They found that the genetic malformation in the acral melanoma tumors was different than the genetic defects of the others.

Most skin cancer tumors feature small flaws in their genetic code. But scientists found in many of the acral melanoma tumors that large chunks of normal DNA coding had been torn off and reattached elsewhere.

Acral melanomas is one of the most aggressive forms of skin cancer. The tumors are mostly found on hairless portions of skin, like palms, the soles of the feet, and the skin underneath toe and fingernails. Marley's tumor first appeared under the nail of his big toe. The cancer eventually spread throughout his body. Marley died in 1981.

Professor Richard Marais, director of the Cancer Research U.K. Manchester Institute and lead researcher of the study into acral melanomas, says their research shows acral melanomas are not caused by UV exposure like other forms of skin cancer are.

"Too much UV radiation from the sun or sunbeds can lead to a build-up of DNA damage that increases skin cancer risk," Marais explained in a press release. "But acral skin cancer is different because the gene faults that drive it aren't caused by UV damage."

"Pinpointing these faults is a major step towards understanding what causes this unique form of cancer, and how it can best be treated," Marais added.

Scientists at the institute hope further research into the origins of acral melanomas' genetic glitches will lead to more effective treatments.

2014 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.

Continue reading here:
New research details rare cancer that killed Bob Marley

Recommendation and review posted by Bethany Smith

A genetic variant that keeps dopamine levels high could lead to personalized training and also benefit personnel in ERs and air traffic control towers

Munitions are loaded onto a drone at a Nevada air base. Controlling these drones, especially in battle, can pose a complex challenge. Credit: U.S. Air Force

For thousands of years generals such as Caesar and Napoleon have molded citizens into soldiers en masse by using the same drills and training techniques for everyone. A recent study suggests how genetic testing could enable more personalized training for today's drone operators who remotely control missile-armed Predators and Reapers.

The small study, funded by the U.S. Air Force Research Laboratory, looked at how different variants of the catechol-O-methyltransferase, or COMT, gene affected peoples multitasking performances. The gene makes an enzyme that breaks down certain neurochemicals such as dopamine, thereby affecting behavior and mood. Humans have three variants of COMT, labeled as Met/Met, Met/Val and Val/Val. These abbreviations refer to the amino acids methionine and valine in certain paired positions in the molecular structure of the enzyme. The Met and Val variants create observable differences in human behavior that have led researchers to nickname COMT the "worrierwarrior" gene.

In the study led by Raja Parasuraman, a psychologist at George Mason University and director of the Center of Excellence in Neuroergonomics, Technology and Cognition, participants trained on a simulation that required them to each control a swarm of six military drones in a battlefield scenario. The results showed that individuals who inherited the Met/Met "worrier" variant had a significant multitasking advantage over those with the Val/Met variant or Val/Val "warrior" variant in terms of how quickly they directed their drones to intercept incoming threats and efficiently destroy enemy aircraft.

Evidently, the Met/Met variant may not degrade neurochemicals as well as the other variants, so that those with the Met/Met allele can better express dopamine in the brains prefrontal cortex, which allows them to perform better in complex multitasking scenarios, Parasuraman says. Other individuals may simply require more time or different training techniques.

Geneticists have already known about this particular advantage of the Met/Met variant based on past experiments that tested multitasking skill using card sorting. But the new study represents one of the first to try replicating such findings in more practical scenarios. Weve gone beyond a simple laboratory task to a more realistic task that has commonalities with real-world tasks, Parasuraman explains.

This also represents one of the few studies to look at the effects of COMT variants across extended training sessions. The study's 99 student participants all underwent two practice sessions lasting seven minutes each before testing their newfound skills in two more seven-minute sessions consisting of "low" and "high" difficulty. As expected, the Met/Met group showed greater improvement in multitasking performance compared with the other two groups during the course of the training.

Such work is at the forefront of neuroergonomic research aimed at designing better systems based on a scientific understanding of the brain. It represents the first genetics paper in Human Factorsa professional society publication focused on improving technological design and training.

Parasuraman hopes to eventually discover the ideal combinations of learning and training techniques for each of the COMT variants. That ability to tailor multitasking training to each individualwhich could include noninvasive brain stimulationcould theoretically benefit both military personnel and civilians such as ER physicians or air traffic controllers. "Knowing individual genotypes may also help further tailor training, Parasuraman says.

Originally posted here:
Multitasking Gene May Help Drone Operators Control Robotic Swarms

Recommendation and review posted by Bethany Smith

DID ALIENS CREATE HUMANS? (EXTRATERRESTRIAL GENETIC ENGINEERING DOCUMENTARY)
DID ALIENS CREATE HUMANS? (EXTRATERRESTRIAL GENETIC ENGINEERING DOCUMENTARY) Evidence clearly indicates that modern man is not the result of a linear evoluti...

By: ParaNormality

See the rest here:
DID ALIENS CREATE HUMANS? (EXTRATERRESTRIAL GENETIC ENGINEERING DOCUMENTARY) - Video

Recommendation and review posted by Bethany Smith

Provo, Utah (PRWEB) August 27, 2014

Tute Genomics is today teaming up with UK-based Patients Know Best the worlds first fully patient controlled medical records system to make precision medicine a reality to patients across the globe.

Operating a cloud-based software platform, Tute Genomics specializes in genome analysis, creating meaningful reports of an individuals full genomic profile that doctors and patients alike can interpret and use to gain meaningful and actionable insights about their health.

The partnership between the two companies will mean that for the first time a patients full genetic profile and one that is easy to work with and understand can be stored within their healthcare record. For the patient, this will ultimately result in receiving healthcare services that are precision-made for their particular condition based on their individual genome sequence.

Dr Reid Robison, CEO of Tute Genomics said,Were enthusiastic about this new partnership with Patients Know Best because we share the same philosophies about pushing genomic medicine forward. Patients Know Best believes in creating a system that will reduce errors and raise quality of healthcare and that is the purpose of the Tute genomics platform; enabling precision medicine. Tute Genomics is working hard to make genomics more accessible to healthcare, research and even consumers, in order to advance individualized, genome-guided medicine.

Over the past few years genomic sequencing 'mapping out' a persons full DNA has become far cheaper and therefore far more feasible. Full genome sequencing involves testing 25,000 separate genomes and 'reading off' 6 billion letters (3 billion base pairs) in any given human genome. Approximately 10 years ago it cost over $100 million to sequence a persons full genome. Today, the cost stands at around $1000.

Dr Mohammad Al-Ubaydli, CEO of Patients Know Best said, When doctors know an individuals genomic profile they can design plans that exactly treat their condition. For example, gene tests can predict whether or not a patient with breast cancer will benefit from a certain type of chemotherapy, or a patient with an infection can safely receive powerful antibiotics. We believe that before long, everyone will get his or her genome sequenced. Tute is providing the most powerful genetic analysis in the hands of patients.

About Patients Know Best Patients Know Best is the worlds first patient-controlled medical records system. It is a fully secure online tool which enables patients to better organise, manage and control their own health care provision it also saves the time of physicians through allowing secure, online consultations. Founded by Dr. Mohammad Al-Ubaydli, a physician, programmer and expert in IT in healthcare, Patients Know Best has won social enterprise awards for its focus on patient care. Patients Know Bests first customers include Great Ormond Street Hospital, St Marks Hospital and NHS South Devon. Patients Know Best integrates fully into the NHS secure network and is available for use by any patient with any clinician anywhere in the world. It is now used by over 30 hospitals in the UK, USA, Holland, Ireland, Kuwait, Australia and Hong Kong. Patients Know Best complies fully with UK NHS information governance requirements as well as the EU data protection act and US HIPAA legislation for dealing with medical data. http://www.patientsknowbest.com

About Tute Genomics Tute Genomics is a USA-based company developing innovative cloud-based solutions to accelerate genetic discovery and enable precision medicine. Tute created a clinical genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Given sequencing data on a genome or a panel of genes, Tute can return over 125 annotations on variants and genes, perform family-based, case/control or tumor sample analyses to identify causal disease genes, and generate clinical reports for clinicians to focus on clinically relevant and actionable findings. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation & interpretation technology with over 800 scientific publications. The genome revolution is here, and Tute envisions a future where clinical reports on genomes are interactive and integrated into medical records, and aims to be the 'dropbox for genomes' for clinicians and patients alike. To learn more please visit http://www.tutegenomics.com.

Contact: Chris Smith, Swarm Communications +44 (0) 7989 321 743 chris(at)swarmcommunications(dot)co.uk

See original here:
Tute Genomics and Patients Know Best Partner to Bring Precision Medicine' a Step Closer

Recommendation and review posted by Bethany Smith

The Sims 3 | Perfect Genetics Challenge Part 22: Like Father, Like Son
In this part, Cassandra finds out shes pregnant and we age up Caleb. The Sims 3 Perfect Genetics Playlist: https://www.youtube.com/playlist?list=PL0BV_YFL-2I77acu9TBO5aor9CgMW97mo Links!...

By: simplyapril

See the original post:
The Sims 3 | Perfect Genetics Challenge Part 22: Like Father, Like Son - Video

Recommendation and review posted by Bethany Smith

Israelites - Genetics, Color, ESAU and Leprosy
An understanding and physical example of Esau, Leprosy and recessive genes.

By: Truenation12

See the article here:
Israelites - Genetics, Color, ESAU and Leprosy - Video

Recommendation and review posted by Bethany Smith

Poor genetics? Naturally weak? Watch this NOW
So you believe that you are naturally weak and have poor muscle building genetics? I have a message for you. Focus on the things you can control, meaning consistency and weekly improvement,...

By: BeardedBeastofDuloc

Go here to read the rest:
Poor genetics? Naturally weak? Watch this NOW - Video

Recommendation and review posted by Bethany Smith

By Jillian Rose Lim

July 24, 2014: Olalla Gomez, 22, a final-year student of English philology who is also on on the first day of her probation period before getting a contract as temporary waiter, holds a mug of beer in the "Los Capeas" restaurant in downtown Ronda, near Malaga, southern Spain.Reuters

Some people get hangovers after a night of drinking, while others don't, and the reason may be in their genes, a new study of twins in Australia suggests.

Researchers looked for links between the study participants' genetic makeups and the number of hangovers the individuals reported experiencing in the past year. The results showed that genetic factors accounted for 45 percent of the difference in hangover frequency in women and 40 percent in men.

In other words, genetics accounts for nearly half of the reason why one person experiences a hangover and another person doesn't, after drinking the same amount of alcohol, the study said. The other half probably comes from outside influences unrelated to DNA, such as how quickly a person drinks, whether they eat while they drink and their tolerance for alcohol.

The researchers also found that the people who had the gene variants involved in an increased risk of having hangovers also drank to the point of being intoxicated more frequently than people who didnt have the hangover genes. That is, the genes that dictate how frequently a person gets hungover may also underlie how frequently someone gets drunk in the first place. This suggests that the findings could contribute to future research on alcohol addiction.

"We have demonstrated that susceptibility to hangovers has a genetic underpinning. This may be another clue to the genetics of alcoholism," study leader Wendy Slutske, a psychology professor at the University of Missouri-Columbia, told Live Science in an email. [7 Ways to Cheat a Hangover]

People who are less susceptible to having a hangover might have a greater risk for alcohol addiction, the researchers said.

In the study, about 4,000 middle-age people from the Australian Twin Registry participated in a telephone survey, reporting their experiences with hangovers and alcohol consumption. The participants recounted how many times they had gotten drunk in the past year, along with their "hangover frequency," which is the number of days in the previous year they felt sick the day after drinking. They also reported their "hangover resistance," which was whether or not they had ever experienced a hangover after getting drunk.

The researchers found a strong correlation between identical twins in reports of hangover frequency as well as hangover resistance, suggesting that the genetic similarities of some twins played a part in their hangover susceptibility.

Original post:
Study finds genetics play role in hangovers

Recommendation and review posted by Bethany Smith